YVER ANTOINE 4
4 · Centessa Pharmaceuticals plc · Filed Feb 3, 2023
Insider Transaction Report
Form 4
YVER ANTOINE
Chief Medical Officer
Transactions
- Award
Ordinary Shares
2023-02-01+77,200→ 821,381 total - Award
Share Option (right to buy)
2023-02-01+115,000→ 115,000 totalExercise: $3.85Exp: 2033-02-01→ Ordinary Shares (115,000 underlying) - Sale
Ordinary Shares
2023-02-01$3.79/sh−7,700$29,201→ 813,681 total
Footnotes (5)
- [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- [F2]The shares reported in this transaction represent Restricted Share Units ("RSUs") issued under the Centessa Pharmaceuticals plc Amended and Restated 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one Ordinary Share of the Issuer. The RSUs shall vest and be settled in four equal annual installments with the first such annual vesting being on February 1, 2024.
- [F3]The sales reported represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted shares. These sales were automatic and intended to qualify under Rule 10b5-1.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.7500 to $3.7950, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F5]1/48th of the shares subject to such option shall vest and become exercisable in equal monthly installments with the first installment vesting on March 1, 2023.